Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 11/20 | 0.32 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.31 |
| ▸ | KLK1 | P06870 | 1/20 | 0.31 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
| ▸ | HTR1F | P30939 | 1/20 | 0.30 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.30 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.30 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16238778 | 0.76 | ADORA2A (0.33) | DGAT2ABL1ADORA2BADORA2AGSK3B | |
| SCHEMBL16238775 | 0.76 | ADORA2A (0.33) | DGAT2ABL1ADORA2BADORA2AGSK3B | |
| SCHEMBL16776196 | 0.76 | CA2 (0.37) | — | |
| SCHEMBL16785631 | 0.75 | TRPV3 (0.39) | DGAT2ABL1KMT2A | |
| SCHEMBL19365870 | 0.75 | HTR1F (0.33) | DGAT2ABL1ADORA2BADORA2AGSK3B | |
| SCHEMBL19706091 | 0.73 | ADORA2A (0.32) | ABL1ADORA2BADORA2AHTR1FCACNA1G | |
| SCHEMBL16785571 | 0.73 | TRPV3 (0.39) | DGAT2ABL1KMT2A | |
| SCHEMBL19365789 | 0.71 | KARS1 (0.35) | ABL1KLKB1KLK1DYRK1AKMT2A | |
| SCHEMBL19365330 | 0.71 | KARS1 (0.35) | ABL1KLKB1KLK1DYRK1AKMT2A | |
| SCHEMBL16776147 | 0.69 | KARS1 (0.35) | ABL1DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | DGAT2 1047/4885ABL1 4089/4885KLKB1 2174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.